Clinical Trials Search
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
This phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread.
-To evaluate the safety of atezolizumab (MPDL3280A) administration in patients who have received ACT within 6 months of enrollment. -To evaluate the expansion of engrafted T cells following atezolizumab administration in the peripheral blood and within the tumor microenvironment. -To evaluate the phenotype and function of engrafted T cells following atezolizumab administration. -To observe and record anti-tumor activity. To evaluate the response rate using irRC and RECIST v1.1, or other tumor-specific criteria. -To evaluate survival outcomes and progression free survival using irRC and RECIST v1.1, or other tumor-specific criteria.